Brookstone Capital Management lessened its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 74.9% during the first quarter, Holdings Channel.com reports. The fund owned 2,930 shares of the exchange traded fund’s stock after selling 8,764 shares during the period. Brookstone Capital Management’s holdings in SPDR S&P Biotech ETF were worth $374,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in XBI. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in SPDR S&P Biotech ETF in the fourth quarter valued at about $27,000. Intesa Sanpaolo Wealth Management acquired a new stake in SPDR S&P Biotech ETF during the fourth quarter worth about $30,000. SHP Wealth Management acquired a new stake in SPDR S&P Biotech ETF during the fourth quarter worth about $31,000. Legacy Wealth Managment LLC ID acquired a new stake in SPDR S&P Biotech ETF during the fourth quarter worth about $32,000. Finally, Smartleaf Asset Management LLC bought a new position in SPDR S&P Biotech ETF in the 4th quarter valued at about $32,000.
SPDR S&P Biotech ETF Stock Performance
Shares of NYSEARCA:XBI opened at $155.38 on Monday. The firm has a 50 day moving average of $135.24 and a 200-day moving average of $128.73. The stock has a market capitalization of $9.91 billion, a PE ratio of 11.47 and a beta of 0.85. SPDR S&P Biotech ETF has a 12 month low of $82.04 and a 12 month high of $155.93.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
